Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antidepressant |
| gptkbp:ATCCode |
N06AA10
|
| gptkbp:CASNumber |
72-69-5
|
| gptkbp:discoveredBy |
1963
|
| gptkbp:eliminationHalfLife |
18–44 hours
|
| gptkbp:has_protein_binding |
93%
|
| gptkbp:hasMolecularFormula |
C19H21N
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nortriptylinum
|
| gptkbp:is_on_WHO_Model_List_of_Essential_Medicines |
true
|
| gptkbp:IUPACName |
3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Aventyl
gptkb:Pamelor |
| gptkbp:metabolism |
gptkb:amitriptyline
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
weight gain increased heart rate drowsiness dry mouth |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
peripheral neuropathy migraine prophylaxis |
| gptkbp:bfsParent |
gptkb:Nortriptyline
|
| gptkbp:bfsLayer |
7
|